Meeting
2016 ASCO Annual Meeting
Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.
Authors
Annick Desjardins
Duke University Medical Center, Durham, NC
Annick Desjardins , John H. Sampson , Katherine B. Peters , Gordana Vlahovic , Dina Randazzo , Stevie Threatt , James Emmett Herndon II, Susan Boulton , Denise Lally-Goss , Frances McSherry , Eric S Lipp , Allan H. Friedman , Henry S. Friedman , Darell D. Bigner , Matthias Gromeier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01491893
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2061)
DOI
10.1200/JCO.2016.34.15_suppl.2061
Abstract #
2061
Poster Bd #
248
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
First Author: Annick Desjardins
Poster
2021 ASCO Annual Meeting
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
First Author: Andrew E. Sloan
Poster
2020 ASCO Virtual Scientific Program
Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).
First Author: Annick Desjardins
Poster
2016 ASCO Annual Meeting
Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).
First Author: Daniela Annenelie Bota